Pharmacotherapeutic estimation of chronic gastritis in conditions of real clinical practice


  • O. O. Gerasymova National University of Pharmacy, Ukraine
  • L. V. Iakovlieva National University of Pharmacy, Ukraine
  • T. V. Morus National University of Pharmacy, Ukraine
  • A. M. Tur National University of Pharmacy, Ukraine



chronic gastritis, clinical and economic analysis, ABC-analysis, VEN-analysis, frequency analysis, formulary system


Clinical and economic analysis of pharmacotherapy in patients with chronic gastritis (CG) in a particular healthcare institution (HCI) of Kharkov has been carried out. As many as 105 history cases of patients with CG aged from 35 to 59 years have been analyzed. The research lasted 6 months in 2013. Using the “formal” VEN-analysis it has been determined that the large majority of medicines (87.23%) prescribed to the patients with CG in the given HCI of Kharkov is presented in the State Formulary of Ukraine (SFU). Based on the results of the frequency analysis it has been found that the medicines mentioned are the most part of prescription medicines (91.15 %). Using the ABC-analysis it has been determined that the major part of costs (86.00 %) connected with pharmacotherapy of patients with CG are spent on them. The approaches for optimization of pharmacotherapy of CG in the given HCI of Kharkov and funds to carry them out have been proposed. In general, the pharmacotherapy prescribed can be considered as rational both from the clinical and economic points of view. Using indicators of the formulary system monitoring the estimation of its introduction level in the given HCI of Kharkov is given. The number of the medicines prescribed from the SFU compared to the total number of prescriptions (the indicator of the process) was 87.23%, and the number of the medicines prescribed for 1 patient (the indicator of the result) was 7.7. The results obtained show both an insufficient level of the formulary system introduction in this HCI and the urgency of further correction of pharmacotherapy of the patients with CG according to the SFU, as well as rationalization of the medicines prescribed for each individual patient.


Державний формуляр лікарських засобів України (п'ятий випуск, 2013 р.). – Режим доступу:

Морозов А. М., Яковлєва Л. В., Бездітко Н. В. та ін. Оцінка клінічної та економічної доцільності використання лікарських засобів у лікувально-профілактичному закладі (супровід формулярної системи): Метод. рекоменд. – Х.: Стиль-Издат, 2013. – 36 с.

Наказ МОЗ України № 918 від 28.10.2010 р. «Про затвердження методичних рекоме-ндацій щодо моніторингу та оцінки дієвості формулярної системи на етапі її впрова-дження». – Режим доступу:

Пошукова система «Стандарти надання медичної допомоги в Україні». – Режим дос-тупу: http: //

Програмний комплекс «Аптека» компанії «Моріон». – Режим доступу:

Akhelova S. // Medical and Health Science Journal. – 2011. – Vol.8. - Р. 111-114.

Camila Alves Areda, Roni Cléber Bonizio, Osvaldo de Freitas. // Brazilian Journal of Pharmaceutical Sciences. – 2011. - Vol. 47, N 2. - Р.231-240.

Esposito D., Migliaccio-Walle K., Molsen E. Reliability and Validity of Data Sources for Outcomes Research & Disease and Health Management Programs. – Lawrenceville, NJ: ISPOR, 2013. – 467 р.

Gupta R., Gupta K., Jain Maj B. et al. // MJAFI. – 2007. – Vol. 63, N 4. – p. 325-327.

Kulkarni U., Dalvi K., Moghe V.V. еt al. // African Journal of Pharmacy and Pharmacology. – 2009. – Vol. 3, N 8. – P. 362-367.

Miller P. An Introduction to Health Economic Evaluation. The NIHR RDS for the East Midlands. – Yorkshire & the Humber, 2009. – 42 р.

Musaraj А., Musaraj А., Dervishi А. // Alexandria Journal of Medicine. – 2014. –Vol.,50, Issue 1. – P. 1–6.

Understanding Health Outcomes and Pharmacoeconomics / edited by MacKinnon E. – Jo-nes & Bartlett Publishers, 2011. – 218 р.

Wandalkar P., Pandit P. T., Zite A. R. // Indian Journal of Basic and Applied Medical Re-search. – 2013. - Vol.3,Issue-1. - P.126-131.